Findings support efforts in ongoing Early Access Program and upcoming clinical trials, and suggest Ampligen’s…
Figure 1 PET scan images showing presence of target enzyme dCK in normal mice (row…
What you need to know: Verizon Business Internet Portal allows customers to view and manage…
SLB will support the CO2 sequestration efforts for the Louisiana Green Fuels Project, capable of…
Bluesky’s ‘Copilot for Snowflake’ helps companies get more value out of their Snowflake Data Cloud…
Innovative distributed SQL processing enables continuous intelligence and faster, more precise business decisions SAN FRANCISCO,…
NAPLES, Fla., June 27, 2023 (GLOBE NEWSWIRE) — Boris Kontsevoi is a technology executive, President…
Toronto, Ontario–(Newsfile Corp. – June 27, 2023) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB:…
Six-week immersive program featuring eight founders concludes with a Generative AI Summit PHILADELPHIA–(BUSINESS WIRE)–Today, Comcast…
Washington, DC-based REQ will support THP’s vision to rapidly scale through strategic investments to create…
Long-standing shareholders to receive a 10% bonus LYON, France & MIDDLETON, Wis.–(BUSINESS WIRE)–Esker, a global…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA releases a report on U.S. commercial mortgage-backed securities (CMBS) loan performance trends…
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical…
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical…
– U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic…
– U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic…
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient…
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient…
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…